Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N. Betge J, et al. Among authors: schulte n. Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19. Digestion. 2016. PMID: 27756074
Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA. Burgermeister E, et al. Among authors: schulte n. Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156678 Free PMC article.
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM, Betge J, Gutting T, Burgermeister E, Belle S, Zhan T, Schulte N, Maenz M, Ebert MP, Haertel N. Meindl-Beinker NM, et al. Among authors: schulte n. BMC Cancer. 2019 Mar 14;19(1):231. doi: 10.1186/s12885-019-5446-2. BMC Cancer. 2019. PMID: 30871493 Free PMC article. Clinical Trial.
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD. Gaiser MR, et al. Among authors: schulte n. Cancer Med. 2019 Aug;8(9):4169-4175. doi: 10.1002/cam4.2132. Epub 2019 Jun 14. Cancer Med. 2019. PMID: 31199595 Free PMC article. Clinical Trial.
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP. Burgermeister E, et al. Among authors: schulte n. EBioMedicine. 2019 Jul;45:139-154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9. EBioMedicine. 2019. PMID: 31300350 Free PMC article.
102 results